



For further information:
Consuelo Trillo Díaz
ctrillo@rovi.es
Tel: + 34 91 244 44 10

INCORPORATION OF A DOCTOR TO THE R&D&i WITHIN THE "TORRES QUEVEDO" PROGRAM 2018 CALL

Madrid – 30 of June 2018

ROVI is a company committed to innovation, this enables it to safeguard its portfolio, composed by over 500 patent dossiers, 399 of which have now been granted, while 106 are in the examination and evaluation phase. Currently, R&D projects of ROVI are mainly focused in glycomics and ISM[®] platform, the latter is a drug release system, owned by ROVI, whose objective is improving patient's adherence to treatment.

ROVI has received the support of the Ministry of Economy and Competitiveness in its Research and Development work through the TORRES QUEVEDO program. This program promotes the recruitment of doctors to develop industrial research projects, experimental development or feasibility studies, in order to promote the professional career of investigators, as well as to stimulate demand, in the private sector, of well trained personnel to undertake R&D plans and projects, and help to consolidate newly created technological companies.

Thanks to the funding received, the staff has been strengthened through the recruitment of a doctor for the implementation of the R&D&i activity within the framework of the project **"Validation of processes involved in the new platform ISM technology developed by Laboratorios Farmacéuticos Rovi"**, Reference nº.: **PTQ-16-08424**.



About ROVI

ROVI is a fully integrated Spanish specialist pharmaceutical company dedicated to research, development, manufacture under license and marketing of small molecules and biological specialties. The Company has a diversified portfolio of products which it has been marketing in Spain through a specialist sales team, devoted to visiting medical specialists, hospitals and pharmacies. ROVI's portfolio, with 30 main products marketed, is currently focused on its flagship product, Bemiparin, a second-generation low-weight heparin developed internally. ROVI's product portfolio in the research and development phase is mainly focused on meeting medical needs that are currently unsatisfied; developing new products based on low-molecular-weight heparins (LMWH) and expanding the indications for existing products also based on LMWH. ROVI manufactures the active ingredient Bemiparin for its main patented products and for the injectable pharmaceutical products developed by its own team of researchers and uses its filling and packaging capacity to offer a wide range of third-party manufacturing services for some of the leading international pharmaceutical companies, mainly in the area of preloaded syringes. For further information, visit www.rovi.es.